UroAlert - GU Oncology Daily

Brian Mazzarella describes the MoonRISe-3 trial design, a global randomized study of erdafitinib intravesical drug-releasing system versus intravesical chemotherapy in FGFR-altered patients with pure papillary non-muscle invasive bladder cancer who have received prior BCG.

This expert panel reviewed the CAPItello-281 Phase III trial, highlighting PTEN loss as a critical prognostic marker identifying a high-risk subset of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and a clear unmet need with standard ADT-based therapy.